Trial Changelog
Source-linked ClinicalTrials.gov change monitoring for investable companies.
965Investable tickers covered
18537Events in last 30 days
14886NCTs touched in last 30 days
2026-01-15 22:52 UTCLast refreshed (UTC)
2026-01-15
No high/medium-impact events.
2026-01-14
16:05
CL
COLGATE PALMOLIVE CO
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07263698
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
16:05
SGIOF
SHIONOGI & CO LTD
MEDIUM
16:05
FSNUY
Fresenius SE & Co. KGaA
MEDIUM
16:05
VRDN
Viridian Therapeutics, Inc.\DE
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07155668
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Status: NOT_YET_RECRUITING → RECRUITING — PHASE3
NCT07223203
• Phase 3 • Status: Not yet recruiting → Recruiting
MEDIUM
16:05
SKYE
Skye Bioscience, Inc.
Primary endpoint added: Change From Baseline in Ocular Hypertension as Measured by Intraocular Pressure (IOP) — PHASE2
NCT06144918
• Phase 2
MEDIUM
16:05
NVS
NOVARTIS AG
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
AZN
ASTRAZENECA PLC
Enrollment 116→118 (2%) — PHASE1, PHASE2
NCT06151964
• Phase 1, Phase 2 • Enrollment 116→118
MEDIUM
16:05
TNGX
Tango Therapeutics, Inc.
Enrollment 308→342 (11%) — PHASE1, PHASE2
NCT06188702
• Phase 1, Phase 2 • Enrollment 308→342
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
SKYE
Skye Bioscience, Inc.
MEDIUM
16:05
BMY
BRISTOL MYERS SQUIBB CO
MEDIUM
16:05
NVS
NOVARTIS AG
Status: RECRUITING → TERMINATED (The study has closed earlier than planned due to one of the ) — PHASE2
NCT05987176
• Phase 2 • Status: Recruiting → Terminated • Why stopped: The study has closed earlier than planned due to one of the funders decision to withdraw the financial support for the s…
MAJOR
16:05
KYMR
Kymera Therapeutics, Inc.
MEDIUM
16:05
BNTX
BioNTech SE
MEDIUM
16:05
AZN
ASTRAZENECA PLC
MEDIUM
16:05
VTRS
Viatris Inc
MEDIUM
16:05
SKYE
Skye Bioscience, Inc.
HIGH
16:05
MRK
Merck & Co., Inc.
MEDIUM
16:05
AZN
ASTRAZENECA PLC
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
DNTH
Dianthus Therapeutics, Inc. /DE/
MEDIUM
16:05
LXRX
LEXICON PHARMACEUTICALS, INC.
MEDIUM
16:05
NVO
NOVO NORDISK A S
MEDIUM
16:05
FOXA
Fox Corp
MEDIUM
16:05
ALNY
ALNYLAM PHARMACEUTICALS, INC.
MEDIUM
16:05
PFE
PFIZER INC
Status: RECRUITING → WITHDRAWN (The study was terminated early as no patients were enrolled.) — PHASE2
NCT06521762
• Phase 2 • Status: Recruiting → Withdrawn • Why stopped: The study was terminated early as no patients were enrolled.
MAJOR
16:05
REGN
REGENERON PHARMACEUTICALS, INC.
MEDIUM
16:05
SKYE
Skye Bioscience, Inc.
Primary endpoint removed: Part C - The nature, frequency, and severity of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and adverse events of special interest (AESIs) — PHASE2
NCT06577090
• Phase 2
MEDIUM
16:05
APGE
Apogee Therapeutics, Inc.
MEDIUM
16:05
BMY
BRISTOL MYERS SQUIBB CO
MEDIUM
16:05
SO
SOUTHERN CO
Status: RECRUITING → SUSPENDED (Pending Protocol Amendment Approval) — PHASE1
NCT05989828
• Phase 1 • Status: Recruiting → Suspended • Why stopped: Pending Protocol Amendment Approval
MAJOR
16:05
ATXS
Astria Therapeutics, Inc.
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
VTRS
Viatris Inc
MEDIUM
16:05
VERX
Vertex, Inc.
MEDIUM
16:05
VTRS
Viatris Inc
MEDIUM
16:05
VRDN
Viridian Therapeutics, Inc.\DE
MEDIUM
16:05
NBIX
NEUROCRINE BIOSCIENCES INC
MEDIUM
16:05
NMRA
Neumora Therapeutics, Inc.
MEDIUM
16:05
AZN
ASTRAZENECA PLC
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
PFE
PFIZER INC
MEDIUM
16:05
VRDN
Viridian Therapeutics, Inc.\DE
MEDIUM
16:05
BMY
BRISTOL MYERS SQUIBB CO
MEDIUM
16:05
ONON
On Holding AG
MEDIUM
16:05
ACHV
ACHIEVE LIFE SCIENCES, INC.
Primary endpoint added: Percentage of Participants With Vaping Abstinence From Week 9 to 12 — PHASE2
NCT05431387
• Phase 2
MEDIUM
2026-01-13
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
MDT
Medtronic plc
MEDIUM
17:30
PFE
PFIZER INC
MEDIUM
17:30
CRNX
Crinetics Pharmaceuticals, Inc.
MEDIUM
17:30
ALC
ALCON INC
MEDIUM
17:30
TAK
TAKEDA PHARMACEUTICAL CO LTD
MEDIUM
17:30
RLYB
Rallybio Corp
Status: COMPLETED → TERMINATED (This study was terminated early by the sponsor due to insuff) — PHASE2
NCT06435845
• Phase 2 • Status: Completed → Terminated • Why stopped: This study was terminated early by the sponsor due to insufficient drug exposure to achieve the intended therapeutic eff…
MAJOR
17:30
NTRA
Natera, Inc.
HIGH
17:30
NVS
NOVARTIS AG
MEDIUM
17:30
EML
EASTERN CO
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
OGN
Organon & Co.
Status: NOT_YET_RECRUITING → RECRUITING — PHASE3
NCT07265479
• Phase 3 • Status: Not yet recruiting → Recruiting
MEDIUM
17:30
AMGN
AMGEN INC
MEDIUM
17:30
CRNX
Crinetics Pharmaceuticals, Inc.
Primary endpoint added: Percentage of Participants Who Maintain Biochemical Response in IGF-1 (≤1.0× the Upper Limit of Normal [ULN]) at the End of the Randomized Control Phase (EOR) — PHASE3
NCT04837040
• Phase 3
MEDIUM
17:30
OGN
Organon & Co.
MEDIUM
17:30
ACRS
Aclaris Therapeutics, Inc.
MEDIUM
17:30
MRK
Merck & Co., Inc.
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
NVMI
NOVA LTD.
MEDIUM
17:30
LXRX
LEXICON PHARMACEUTICALS, INC.
Enrollment 18→6 (-67%) — PHASE1, PHASE2
NCT07218887
• Phase 1, Phase 2 • Enrollment 18→6
MEDIUM
17:30
PFE
PFIZER INC
Status: NOT_YET_RECRUITING → WITHDRAWN (Strategic decision to cancel the study based on adjusted cli) — PHASE3
NCT06103734
• Phase 3 • Status: Not yet recruiting → Withdrawn • Why stopped: Strategic decision to cancel the study based on adjusted clinical development plan.
MAJOR
17:30
PFE
PFIZER INC
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
NVS
NOVARTIS AG
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
EW
Edwards Lifesciences Corp
MEDIUM
17:30
AZN
ASTRAZENECA PLC
MEDIUM
17:30
AZN
ASTRAZENECA PLC
MEDIUM
17:30
NVS
NOVARTIS AG
MEDIUM
17:30
QNCX
Quince Therapeutics, Inc.
MEDIUM
17:30
NVS
NOVARTIS AG
MEDIUM
17:30
CHRS
Coherus Oncology, Inc.
MEDIUM
17:30
TLX
Telix Pharmaceuticals Ltd
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
NVS
NOVARTIS AG
MEDIUM
17:30
BRO
BROWN & BROWN, INC.
Primary endpoint removed: Change in Knowledge of Firearm Injuries in the US — NA
NCT04804189
• Na
MEDIUM
17:30
BNTX
BioNTech SE
HIGH
17:30
SNY
Sanofi
MEDIUM
17:30
MRK
Merck & Co., Inc.
MEDIUM
17:30
NTRA
Natera, Inc.
MEDIUM
17:30
LYEL
Lyell Immunopharma, Inc.
MEDIUM
17:30
MDT
Medtronic plc
MEDIUM
17:30
ALC
ALCON INC
Status: RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07082816
• Phase 3 • Status: Recruiting → Active, not recruiting
MEDIUM
17:30
LLY
ELI LILLY & Co
MEDIUM
17:30
NVCR
NovoCure Ltd
MEDIUM
17:30
BNTX
BioNTech SE
MEDIUM
17:30
SYRE
Spyre Therapeutics, Inc.
MEDIUM
2026-01-12
15:49
BIIB
BIOGEN INC.
MEDIUM
15:49
CDZI
CADIZ INC
MEDIUM
15:49
AZN
ASTRAZENECA PLC
MEDIUM
15:49
AZN
ASTRAZENECA PLC
MEDIUM
15:49
GILD
GILEAD SCIENCES, INC.
MEDIUM
15:49
BMY
BRISTOL MYERS SQUIBB CO
MEDIUM
15:49
GILD
GILEAD SCIENCES, INC.
Status: RECRUITING → TERMINATED (Poor recruitment) — PHASE4
NCT03696290
• Phase 4 • Status: Recruiting → Terminated • Why stopped: Poor recruitment
MAJOR
15:49
BHVN
Biohaven Ltd.
MEDIUM
15:49
BHVN
Biohaven Ltd.
MEDIUM
15:49
GILD
GILEAD SCIENCES, INC.
MEDIUM
15:49
IMNN
Imunon, Inc.
Enrollment 50→30 (-40%) — PHASE1, PHASE2
NCT05739981
• Phase 1, Phase 2 • Enrollment 50→30
MEDIUM
15:49
GILD
GILEAD SCIENCES, INC.
MEDIUM
15:49
ALC
ALCON INC
MEDIUM
15:49
REGN
REGENERON PHARMACEUTICALS, INC.
MEDIUM
15:49
ALNY
ALNYLAM PHARMACEUTICALS, INC.
MEDIUM
15:49
MRK
Merck & Co., Inc.
Enrollment 228→298 (31%) — PHASE1, PHASE2
NCT06780111
• Phase 1, Phase 2 • Enrollment 228→298
MEDIUM
2026-01-11
No high/medium-impact events.
2026-01-10
No high/medium-impact events.
2026-01-09
No high/medium-impact events.